Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
about
The Regulation of NF-κB Subunits by Phosphorylationc-Rel and its many roles in cancer: an old story with new twistsThe cnidarian origin of the proto-oncogenes NF-κB/STAT and WNT-like oncogenic pathway drives the ctenophores (Review)CluGene: A Bioinformatics Framework for the Identification of Co-Localized, Co-Expressed and Co-Regulated Genes Aimed at the Investigation of Transcriptional Regulatory Networks from High-Throughput Expression Data.Overexpression of an activated REL mutant enhances the transformed state of the human B-lymphoma BJAB cell line and alters its gene expression profileSer484 and Ser494 in REL are the major sites of IKK phosphorylation in vitro: evidence that IKK does not directly enhance GAL4-REL transactivation.Deletion analysis and alternative splicing define a transactivation inhibitory domain in human oncoprotein RELHistone acetyltransferase p300 is a coactivator for transcription factor REL and is C-terminally truncated in the human diffuse large B-cell lymphoma cell line RC-K8.The c-Rel Transcription Factor in Development and Disease.CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.Alternative splicing in the NF-kappaB signaling pathway.Specification of DNA binding activity of NF-kappaB proteinsSignaling mediated by the NF-κB sub-units NF-κB1, NF-κB2 and c-Rel differentially regulate Helicobacter felis-induced gastric carcinogenesis in C57BL/6 mice.The diverse and complex roles of NF-κB subunits in cancer.CHFR, a potential tumor suppressor, downregulates interleukin-8 through the inhibition of NF-kappaB.NF-κB in Hematological Malignancies.
P2860
Q26752951-251C94B1-EABE-4046-B78A-F37AFB436D99Q26772234-9FBAFBB8-488C-4E6B-BD1E-79756812C620Q26799398-5B1C55EE-C552-4F66-9040-BD90F2E0F70DQ30653046-3C335F6D-9D55-4FF0-9E8E-4AFAC77B0E5BQ33551720-FAFD6D76-5757-4CCF-A5E1-8F91BE3336DBQ33658906-5F4EFCE6-9BAC-4CF9-9963-FE0F8AD45DAEQ33706844-541059DA-6281-47E3-8B0B-9DD829EEB3B1Q33770877-AB198B5D-3E65-4959-8334-58DE4B8084F8Q35556506-C4333E17-579A-4912-AEA5-38068F9BA13AQ36949574-BADFACF8-5585-4A44-A2CF-D2E6CA84A1B6Q37057998-60FAAE45-E57A-422B-A794-54DD67221C30Q37412645-31A7F48B-8D97-48F0-8D19-98139AA1F1EFQ37502584-AC8A8D69-8B5D-4E10-9245-F71463F232E3Q37976939-9F99309C-93ED-40E7-975A-B2683307FA4EQ39850171-0CE36120-DAD3-499E-93D1-E4CD30F33148Q54147337-0C00C3F9-EDA4-4A4F-8C79-8209BBA864C0
P2860
Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Mutation of an IKK phosphoryla ...... n vitro transforming activity.
@en
Mutation of an IKK phosphoryla ...... n vitro transforming activity.
@nl
type
label
Mutation of an IKK phosphoryla ...... n vitro transforming activity.
@en
Mutation of an IKK phosphoryla ...... n vitro transforming activity.
@nl
prefLabel
Mutation of an IKK phosphoryla ...... n vitro transforming activity.
@en
Mutation of an IKK phosphoryla ...... n vitro transforming activity.
@nl
P2093
P2860
P356
P1433
P1476
Mutation of an IKK phosphoryla ...... n vitro transforming activity.
@en
P2093
Gilmore TD
Starczynowski DT
Trautmann H
P2860
P2888
P304
P356
10.1038/SJ.ONC.1210089
P407
P577
2006-10-30T00:00:00Z
P5875
P6179
1007089690